Market Closed -
Nasdaq
16:00:00 2024-05-15 EDT
5-day change
1st Jan Change
42.31
USD
+0.17%
+0.59%
-0.21%
This article is reserved for members
Not a member ?
Free registration
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing
05-14
MT
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-08
CI
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
04-18
MT
Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study
04-18
MT
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study
04-18
RE
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson?s Disease
04-18
CI
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation
03-25
MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing
03-04
MT
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
02-27
CI
Sector Update: Health Care Stocks Gain Late Afternoon
02-22
MT
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions
02-22
MT
Phew! The party continues!
02-22
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports
02-21
RE
North American Morning Briefing : Stock Futures -2-
02-21
DJ
AbbVie CEO to Retire; COO Robert Michael Named Successor
02-20
MT
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating
02-15
MT
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase
02-13
AN
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance
02-12
MT
AbbVie 4Q Sales Lower as Himura Revenue Sinks
02-02
DJ
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals
02-02
RE
Neumora Therapeutics Names Kaya Pai Panandiker as Chief Commercial Officer
01-22
MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $424,700, According to a Recent SEC Filing
12-28
MT
JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating
12-28
MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $331,608, According to a Recent SEC Filing
12-27
MT
Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40
12-22
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimerâs disease psychosis, epilepsy, panic disorder and Parkinsonâs disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinsonâs disease.
More about the company
Last Close Price
42.31
USD
Average target price
44.78
USD
Spread / Average Target
+5.83%
Consensus
1st Jan change
Capi.
-0.21% 7.71B +7.52% 113B +11.38% 106B -12.64% 22.22B +0.38% 22.27B -4.18% 19.43B -37.85% 17.87B -8.58% 17.24B +37.41% 12.52B -23.95% 8.34B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**